P2s at AUA2025: Clinical trials reshaping urology
From kidney stone management to bladder cancer breakthroughs, these high-impact studies are poised to redefine patient care.
The practice-changing, paradigm-shifting clinical trials in urology (P2s) series at the AUA Annual Meeting highlights the latest data with the greatest potential to transform urological care. AUA2025 was no exception. Two standout sessions—on renal stone treatment and bladder cancer management—provided early evidence that may soon influence everyday clinical decisions.
In “Renal Stone Care Reimagined,” three randomized trials challenged long-held assumptions about kidney stone treatment. The PUSH trial showed that increasing fluid intake did not significantly improve stone-free outcomes. A second trial found no significant differences in outcomes between thulium fiber and high-powered Holmium:YAG lasers, suggesting that either laser is an acceptable choice. And finally, the remaining trial found that patients who did not receive stents after uncomplicated ureteroscopy reported less pain and better satisfaction without added risk.
In “Novel Interventions Show Promise in Bladder Cancer,” two emerging agents were highlighted for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy, produced a complete response in 75.5% of patients. Meanwhile, the TAR-200 device, which delivers gemcitabine directly into the bladder, demonstrated an 82.4% complete response rate. These investigational therapies are being further studied and could offer bladder-sparing alternatives in the near future.
